share_log

Amicus Therapeutics Analyst Ratings

Amicus Therapeutics Analyst Ratings

Amicus 治疗分析师评级
Benzinga ·  2023/09/29 07:24
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/29/2023 60.2% JP Morgan $17 → $19 Maintains Overweight
07/11/2023 26.48% Morgan Stanley $15 → $15 Reiterates Equal-Weight → Equal-Weight
03/28/2023 43.34% B of A Securities $16 → $17 Maintains Buy
03/02/2023 43.34% UBS $15 → $17 Maintains Buy
03/02/2023 -7.25% Goldman Sachs $10 → $11 Maintains Neutral
01/18/2023 34.91% BTIG $14 → $16 Maintains Buy
11/08/2022 26.48% Morgan Stanley $14 → $15 Maintains Equal-Weight
09/09/2022 18.04% Morgan Stanley → $14 Initiates Coverage On → Equal-Weight
02/24/2022 18.04% SVB Leerink $16 → $14 Maintains Outperform
01/14/2022 34.91% SVB Leerink $12 → $16 Upgrades Market Perform → Outperform
01/13/2022 26.48% Cantor Fitzgerald $16 → $15 Maintains Overweight
11/15/2021 34.91% Stifel $12 → $16 Upgrades Hold → Buy
09/30/2021 34.91% JP Morgan → $16 Upgrades Neutral → Overweight
09/30/2021 1.18% SVB Leerink $13 → $12 Maintains Market Perform
05/27/2021 — Needham Initiates Coverage On → Hold
05/21/2021 34.91% UBS → $16 Initiates Coverage On → Buy
04/14/2021 — Cantor Fitzgerald Upgrades Neutral → Overweight
03/22/2021 9.61% SVB Leerink $15 → $13 Maintains Market Perform
03/02/2021 9.61% Stifel → $13 Initiates Coverage On → Hold
02/12/2021 43.34% Cantor Fitzgerald $30 → $17 Downgrades Overweight → Neutral
02/12/2021 60.2% JP Morgan → $19 Downgrades Overweight → Neutral
02/12/2021 26.48% SVB Leerink $30 → $15 Downgrades Outperform → Market Perform
12/14/2020 152.95% SVB Leerink $24 → $30 Maintains Outperform
11/11/2020 77.07% Berenberg → $21 Initiates Coverage On → Hold
11/06/2020 102.36% SVB Leerink $19 → $24 Maintains Outperform
08/11/2020 68.63% Citigroup $15 → $20 Maintains Buy
06/17/2020 60.2% BTIG → $19 Initiates Coverage On → Buy
02/04/2020 68.63% Cantor Fitzgerald $19 → $20 Assumes → Overweight
04/05/2019 — Janney Montgomery Scott Initiates Coverage On → Buy
01/30/2019 68.63% Cantor Fitzgerald → $20 Initiates Coverage On → Overweight
01/17/2019 — Citigroup Upgrades Neutral → Buy
12/18/2018 51.77% Guggenheim → $18 Initiates Coverage On → Buy
10/29/2018 1.18% Citigroup → $12 Initiates Coverage On → Neutral
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
09/29/2023 60.2% 摩根大通 $17→$19 维护 超重
07/11/2023 26.48% 摩根士丹利 $15→$15 重申 等重→等重
03/28/2023 43.34% B of A证券 $16→$17 维护 买
03/02/2023 43.34% 瑞银集团 $15→$17 维护 买
03/02/2023 -7.25% 高盛 $10→$11 维护 中性
01/18/2023 34.91% BTIG $14→$16 维护 买
11/08/2022 26.48% 摩根士丹利 $14→$15 维护 等重
09/09/2022 18.04% 摩根士丹利 →$14 开始承保 →等重
02/24/2022 18.04% SVB Leerink $16→$14 维护 跑赢大盘
2022年01月14日 34.91% SVB Leerink $12→$16 升级 市场表现优于→
2022年01月13日 26.48% 康托·菲茨杰拉德 $16→$15 维护 超重
2021年11月15日 34.91% Stifel $12→$16 升级 持有→购买
09/30/2021 34.91% 摩根大通 →$16 升级 中性→超重
09/30/2021 1.18% SVB Leerink $13→$12 维护 市场表现
2021/05/27 - 李约瑟 开始承保 →保留
2021/05/21 34.91% 瑞银集团 →$16 开始承保 →购买
04/14/2021 - 康托·菲茨杰拉德 升级 中性→超重
03/22/2021 9.61% SVB Leerink $15→$13 维护 市场表现
03/02/2021 9.61% Stifel →$13 开始承保 →保留
02/12/2021 43.34% 康托·菲茨杰拉德 $30→$17 评级下调 超重→中性
02/12/2021 60.2% 摩根大通 →$19 评级下调 超重→中性
02/12/2021 26.48% SVB Leerink $30→$15 评级下调 跑赢→市场表现
12/14/2020 152.95% SVB Leerink $24→$30 维护 跑赢大盘
11/11/2020 77.07% 贝伦伯格 →$21 开始承保 →保留
11/06/2020 102.36% SVB Leerink $19→$24 维护 跑赢大盘
2020年08月11日 68.63% 花旗集团 $15→$20 维护 买
06/17/2020 60.2% BTIG →$19 开始承保 →购买
02/04/2020 68.63% 康托·菲茨杰拉德 $19→$20 假设 →超重
2019年05月04日 - 詹尼·蒙哥马利·斯科特 开始承保 →购买
2019年01月30日 68.63% 康托·菲茨杰拉德 →$20 开始承保 →超重
2019年01月17日 - 花旗集团 升级 中性→购买
2018年12月18日 51.77% 古根海姆 →$18 开始承保 →购买
2018年10月29日 1.18% 花旗集团 →$12 开始承保 →中性

What is the target price for Amicus Therapeutics (FOLD)?

Amicus Treeutics(Fold)的目标价格是多少？

The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by JP Morgan on September 29, 2023. The analyst firm set a price target for $19.00 expecting FOLD to rise to within 12 months (a possible 60.20% upside). 7 analyst firms have reported ratings in the last year.

摩根大通于2023年9月29日报道了Amicus治疗公司(纳斯达克：折叠)的最新目标价。这家分析公司将目标价定为19.00美元，预计市盈率将在12个月内上升至60.20%。去年有7家分析公司公布了评级。

What is the most recent analyst rating for Amicus Therapeutics (FOLD)?

Amicus Treeutics(Fold)的最新分析师评级是多少？

The latest analyst rating for Amicus Therapeutics (NASDAQ: FOLD) was provided by JP Morgan, and Amicus Therapeutics maintained their overweight rating.

对Amicus Treeutics(纳斯达克：折叠)的最新分析师评级由摩根大通提供，Amicus治疗公司维持其增持评级。

When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?

Amicus Treeutics(Fold)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on September 29, 2023 so you should expect the next rating to be made available sometime around September 29, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Amicus Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Amicus治疗公司的上一次评级是在2023年9月29日提交的，所以你应该预计下一次评级将在2024年9月29日左右的某个时候提供。

Is the Analyst Rating Amicus Therapeutics (FOLD) correct?

分析师对Amicus Treeutics(Fold)的评级正确吗？

While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a maintained with a price target of $17.00 to $19.00. The current price Amicus Therapeutics (FOLD) is trading at is $11.86, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Amicus Treeutics(Fold)评级保持不变，目标价在17.00美元至19.00美元之间。目前Amicus治疗公司(Fold)的交易价格为11.86美元，超出了分析师的预测范围。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发